COPD: chronic obstructive pulmonary disease; CPET: cardiopulmonary exercise test; ET: endurance time; ESWT: endurance shuttle walking test; FDC: fixed-dose combinations; FEV 1 : forced expiratory volume in one second; HRQoL: health-related quality of life; IC: inspiratory capacity; ISWT: incremental shuttle walking test; LABA: long-acting β2-agonist;
Introduction
Exercise limitation, driven predominantly by activity-related breathlessness, is an important feature of chronic obstructive pulmonary disease (COPD) that compromises activities of daily living, leading to physical deconditioning and reduced quality of life [1] . This is the reason why improving dyspnoea and exercise tolerance are now recognised as important goals in the treatment of stable COPD and, consequently, direct assessment of the effects of interventions on exercise performance is relevant for COPD [2] .
Although activity limitation in COPD is multifactorial, there is now compelling evidence that the intensity and quality of dyspnea during exercise in patients with COPD is influenced by the time to onset of critical mechanical volume constraints that are ultimately dictated by the magnitude of resting inspiratory capacity (IC) [3] . Lung hyperinflation is thought to represent a mechanical link between the characteristic expiratory airflow impairment, dyspnea, and exercise capacity [3] . Accordingly, therapies aimed at partially reversing pulmonary hyperinflation represent the first step in improving dyspnea and exercise capacity. There has recently been interest in measuring increases in IC as a surrogate measure of lung deflation during exercise in response to bronchodilator treatment in COPD. In general, long-acting bronchodilators have been proven to be able to reduce hyperinflation and therefore to improve dyspnea and tolerance to physical activity [4] , and recently studies have demonstrated their effectiveness in improving both IC and exercise endurance time (ET) [5, 6] .
Nevertheless, it has been suggested that further data on the benefits of long-acting bronchodilators on exercise tolerance are needed [5] .
In these last years, the interest in the use of bronchodilators in COPD is gradually shifting towards the dual bronchodilation, i.e. the simultaneous use of two bronchodilators with different mechanisms of action. Several once-or twice-daily longacting muscarinic antagonist (LAMA)/long-acting β 2 -agonist (LABA) fixed-dose combinations (FDCs) have been developed because of the solid documentation that dual bronchodilation is superior to monotherapy with regards to classical markers of airflow limitation [7] [8] [9] . The impact of almost all LAMA/LABA FDCs on exercise endurance and lung function has also been assessed. Apparently, LABA/LAMA FDCs extend the improvements seen with single agents.
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A C C E P T E D ACCEPTED MANUSCRIPT 5 However, we still do not know if dual bronchodilation is consistently better than monocomponents in positively influencing exercise endurance and IC and, consequently, if it is more appropriate to treat patients with dual bronchodilation instead of single components when the aim of treatment is to improve dyspnea and exercise tolerance in COPD. In order to give an answer to these questions, we have carried out a pair-wise and network meta-analysis to evaluate the impact of LABA/LAMA combination on exercise capacity and lung hyperinflation in COPD. Actually, the meta-analytic method permits to derive estimates of effect across studies, to measure and investigate differences among interventions, and to interpret the obtained findings [10] .
Materials and methods

Searching strategy
This pair-wise and network meta-analysis has been registered in PROSPERO ( Meta-Analyses (PRISMA) Statement ( Figure 1 ) [11] . Furthermore, this synthesis satisfied all the recommended items reported by the PRISMA-P 2015 checklist [12] .
We undertook a comprehensive literature search for RCTs on exercise capacity lasting at least 2 weeks that examined the influence of treatment with LABAs and LAMAs administered in combination in patients suffering from COPD, diagnosed by pulmonary function testing.
The terms "exercise test", AND "COPD", AND/OR "combination", AND/OR "therapy" with the previously mentioned criteria, and any difference in opinion about eligibility was resolved by consensus.
Quality score, risk of bias and evidence profile
The Jadad score, with a scale of 1 to 5 (score of 5 being the best quality), was used to assess the quality of the RCTs concerning the likelihood of biases related to randomisation, double blinding, withdrawals and dropouts [9] .
Two reviewers independently assessed the quality of individual studies, and any difference in opinion about the quality score was resolved by consensus.
The risk of publication bias was assessed by applying the funnel plot and Egger test through the following regression equation: SND = a + b × precision, where SND represents the standard normal deviation (treatment effect divided by its standard error
[SE]), and precision represents the reciprocal of the standard error. Evidence of asymmetry from Egger's test was considered to be significant at P<0.1, and the graphical representation of 90% confidence bands have been presented [9] .
The quality of the evidence has been assessed in agreement with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system [14] either overall for all the studies included in the synthesis, and for the subset metaanalyses.
Data extraction
Data from included studies were extracted and checked for study characteristics and duration, doses of medication, patient characteristics, age, gender, smoking habits, FEV 1 , IC, exercise tests characteristics and Jadad score [9] .
shuttle walking test (ISWT), and IC assessed via integrated volume measured by pneumotachograph.
Data analysis
We performed both a pair-wise and network meta-analysis to evaluate the impact of LABA/LAMA combination on exercise capacity and lung hyperinflation in COPD.
Since data have been selected from a series of studies performed by researchers operating independently, and a common effect size cannot be assumed, we used the random-effects model to perform the pair-wise meta-analysis in order to balance the study weights and to adequately estimate the 95% confidence interval (95%CI) of the mean distribution of drugs effect on the investigated variable.
Considering that ET was investigated via different exercise tests and, consequently, the resulting outcomes were not standardized, we standardized ET results before combining them in the meta-analysis by using the following formula: SMD = (difference in mean outcome between groups) * (standard deviation of outcome among 50.000; tuning interval: 10), the convergence diagnostics for consistency and inconsistency was assessed by using the Brooks-Gelman-Rubin method [16] . Results of network meta-analysis have been expressed as relative effect (RE) and 95% credible level (95%Crl). Due to the complex evidence structure, the inconsistency of evidence has been assessed in addition to heterogeneity obtained from the pair-wise metaanalysis. While heterogeneity represents between-study variation in the measured relative effect of a pair of treatments, inconsistency can only occur when one of the treatment has a different effect when it is compared with the others [17] . The probability that each intervention arm was the most effective was calculated by counting the
proportion of iterations of the chain in which each intervention arm had the highest mean difference, and the surface under the cumulative ranking curve (SUCRA),
representing the summary of these probabilities, was also calculated. The SUCRA is 100% when a treatment is certain to be the best, and 0% when a treatment is certain to be the worst [18] . Subset analysis has been performed via SUCRA according with the airflow limitation.
The optimal information size (OIS) was calculated [19, 20] , and the statistical significance was assessed for P<0.05.
The OpenMetaAnalyst and GeMTC [21] software were used for performing the metaanalysis, GraphPad Prism (CA, USA) software to graph the data, and GRADEpro to assess the quality of evidence [14] . The statistical significance was assessed for P<0.05, and moderate to high levels of heterogeneity were considered for I 2 >50%.
Results
Study characteristics
Results obtained from 1,632 COPD patients were selected from 6 published and unpublished studies [22] [23] [24] [25] [26] [27] including 8 RCTs (Table 1 , Figure 2 ). The studies of Maltais et al. [24] and O'Donnell et al. [27] reported the data of two replicate RCTs each.
The period of treatment ranged from 2 to 12 weeks. Four studies [22] [23] [24] 27 ] had a Jadad score ≥3, whereas for two RTCs [25, 26] the Jadad score was not calculable because data were extracted from abstracts presented at International Congresses.
Pair-wise meta-analysis
The treatment with LABA/LAMA combination significantly improved both the ET (SMD, units of standard deviation: 0.15, 95%CI 0.07 -0.23; P<0.001) and IC (MD, ml: 92.73, 95%CI 73.69 -111.77; P<0.001), vs. monocomponents ( Figure 3A and B Figure 3A [22] .
Network meta-analysis
The network meta-analysis showed that LABA/LAMA combinations significantly Figure 4B ).
LABA/LAMA combinations showed the highest probability of being the best therapy with regard of both ET and IC (100% and 100%, respectively), as confirmed by SUCRA analysis that indicated the following rank of effectiveness: LABA/LAMA combination >> LAMA > LABA > placebo ( Table 2 ).
Subset analysis demonstrated that combining a LABA with a LAMA was always the best therapeutic option regardless of the level of airflow limitation. The analysis of RCTs that enrolled mostly GOLD II patients did not show difference between LABAs and LAMAs administered as monocomponents on both EC and IC. On the other hand, the benefit induced by LAMAs on both EC and IC was considerable greater than that induced by LABAs in patients with larger airflow limitation (mostly GOLD II-III) ( Table 3) . Overall, all the RCTs included in this meta-analysis were characterized by high quality concerning the likelihood of bias related with randomisation, double blinding, withdrawals and dropouts. The results of only one RCT [23] were inconsistent when compared with those of the other studies, by eliciting the so called "small study effect"
Bias and quality of evidence
and inducing the tendency for treatment effect estimates to be greater than those in larger studies.
The cumulative number of enrolled COPD patients in the studies reached the OIS for a binary outcome meta-analysis for both ET (OIS: 1,182; delta: +421) and IC (OIS: 455; delta: +1,030).
The GRADE approach indicated high quality of evidence for the impact of LABA/LAMA combinations vs. monocomponents on both ET and IC (Table 4 ).
Taken together, these findings indicate that the results of this pair-wise and network meta-analysis are robust and reliable.
Discussion
The results of this meta-analysis demonstrate that LABA/LAMA combination is consistently superior to monocomponents, and LAMAs are more effective than LABAs in improving ET and IC. Since studies with no calculable Jadad score may affect the results of a meta-analysis, we have performed a sensitivity analysis by including exclusively studies that had a Jadad score ≥3. The sensitivity analysis confirmed the overall results obtained for both ET and IC.
Our data also show that LABA/LAMA combination increased the ET of ≃60 sec vs. placebo, with lower 95%CI of ≃43 sec, values that fit with the minimal clinical important difference (MCID) estimates of submaximal exercise ET on a cycle ergometer and endurance shuttle walking test ranging between 45 sec and 105 sec [1, 28] .
Furthermore, LABA/LAMA combination increased the IC of ≃229 ml vs. placebo.
Unfortunately, the MCID for IC has yet to be determined and, thus, no accepted MCID
for this variable is currently available [29, 30] , although the European Respiratory Society exercise endurance task force has recently suggested that changes in IC between 140 ml and 200 ml after the administration of bronchodilators may be associated with significantly increased exercise endurance time in moderate-to-severe COPD patients [31] .
We did not find heterogeneity for IC, a variable that was assessed in a homogeneous manner across the analysed studies. However, a substantial level of heterogeneity was detected for ET that was most likely related with the intrinsic characteristics of the analysis carried out on this variable. In fact, since ET was investigated via different exercise tests throughout the studies included in this meta-analysis (i.e. CPET, ESWT, and ISWT), it was not possible to standardize the resulting outcomes. Therefore, we applied the SMD approach instead of the MD analysis. In any case, the overall analysis of bias and quality of evidence indicate that the results of this meta-analysis are robust and reliable with regard of both ET and IC.
The MCID values are usually identified in the context of placebo-controlled RCTs, in which the measured treatment effects may be large, but for trials comparing active treatments, the differences between treatments may be smaller [28] . Our data indicate that there is an interesting signal of a likely clinically important change induced by dual bronchodilation when compared with LABAs, with an increase of ET of ≃43 sec and IC of ≃107 ml, whereas a lower and perhaps not clinically relevant improvement was detected versus LAMAs (≃22 sec and ≃87 ml, respectively). Nevertheless, our figures suggest that LABA/LAMA combinations have the highest probability of being the best therapy with regard of both ET and IC, with the following rank of effectiveness:
LABA/LAMA combination >> LAMA > LABA > placebo.
The superior impact of LABA/LAMA combination than monocomponents on hyperinflation was to be expected considering the results of in vitro studies documenting the greater effectiveness of the LABA/LAMA combination on human small airways, compared with the partial effect of LAMA or LABA alone [32, 33] . We believe that this finding is of particular clinical relevance for improving air-trapping related to the obstruction of bronchioles. In fact, as airway patency over time increases with longer duration of a more potent bronchodilator action, emptying of peripheral airways with trapped air is facilitated, thus reducing hyperinflation and improving breathing M A N U S C R I P T
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mechanics ("pharmacological lung volume reduction") [34] and, consequently, enhancing the exercise capacity.
The results of our study are a significant step forward compared to the review of Liesker and colleagues published in 2002 [35] . In particular, we have provided a pragmatic synthesis of the most recent available data concerning the effects of the so-called ''dual bronchodilator therapy" on exercise capacity and lung hyperinflation in patients with COPD. We must point out that evidences generated by our meta-analysis are of high quality, as indicated by the GRADE analysis. We must also highlight that we have not used a network approach that included studies of a single LABA or LAMA vs. placebo because we strongly believe that, regardless of the LAMA/LABA combination examined, dual bronchodilation is always more effective than the LAMA or LABA alone in terms of the improvement in lung function [9] .
In this context, we must dutifully remark that, as already stressed in the past, we also strongly believe that the effectiveness of dual bronchodilation should always be compared with at least one of the monocomponents included in the FDCs, and not with different LABAs or LAMAs [36] . In fact, it should be obvious that comparing LABA/LAMA combinations with monocomponents characterised by different pharmacokinetics and pharmacodynamics represents a strict pharmacological matter, and not a merely statistical problem that may be solved by performing a subgroup analysis [36] . This is the reason why our meta-analysis did not take into account two FDCs, glycopyrronium/indacaterol and aclidinium/formoterol, already on the market. The effects of glycopyrronium/indacaterol on lung hyperinflation and physical activity in patients with moderate to severe COPD have been successfully evaluated in two studies [37, 38] , but a study compared this FDC vs. placebo [37] and the other glycopyrronium/indacaterol vs. placebo and tiotropium [38] , a LAMA not present in the while others may not. Pooling data from several RCTs could increase the power in order to adequately detect subgroups of responders, but this approach would require to use individual rather than global data that, unfortunately, are not currently accessible to independent researchers. However, in order to assess whether patients with different stages of COPD severity may have a different response to bronchodilators with regard of exercise capacity and lung hyperinflation, we have performed a subset analysis according with the GOLD stage. Intriguingly, the subset analysis confirms that LABA/LAMA combination is always the best therapeutic option regardless of airflow limitation. However, while LABAs were as effective as LAMAs in less severe patients, in more severe COPD patients the impact of LAMAs on both ET and IC was considerably greater than that of LABAs. These findings suggest that, although lung hyperinflation and exercise capacity are different issues, these variables are related with the specific response to pharmacological treatments not only in subjects with more severe airflow limitation, but also in less severe COPD patients in whom leg fatigue could overwhelm the improvement in lung function.
Conclusion
This quantitative synthesis has clearly demonstrated that if the goal of the therapy is to enhance exercise capacity in patients with COPD, only dual LABA/LAMA combination consistently met the putative MCIDs for both ET and IC and in this respect, was superior to the monocomponents. It follows that for patients with persistent troublesome dyspnea and exercise intolerance initiation of dual bronchodilator therapy would seem to be a reasonable first step in management. However, the optimal test for assessment of the impact of a therapeutic intervention on exercise capacity remains to be determined. -For patients with persistent troublesome dyspnea and exercise intolerance initiation of dual bronchodilator therapy would seem to be a reasonable first step in management of COPD.
-However, the optimal test for assessment of the impact of a therapeutic intervention on exercise capacity remains to be determined. 
